Back to Key People
Zhang Lei

Zhang Lei

Founder of Hillhouse; author of Value
Founder & CEO, Hillhouse Capital

Long-termism: be a friend of time, and back "determined practitioners with grand vision." Refuses to trade for trading's sake; values long-run value creation and ever-deepening moats, and will concentrate or go contrarian when warranted.

Founded Hillhouse in 2005 with backing from Yale's endowment; built it into one of Asia's largest investment firms. Early conviction in Tencent and JD; led Gree's mixed-ownership reform and the Belle buyout, spanning private and public markets across consumer, healthcare, tech and clean energy. Author of Value.

Disclosure

Hillhouse files a quarterly U.S. SEC 13F through HHLR Advisors; weights and changes below are from the latest filing (as of Mar 31, 2026). Note this is only a sliver of the firm, which spans private and public markets. Its A-share/HK book is not in the 13F — its former heavyweight LONGi was cut hard and dropped out of the top-10 holders by Q1 2026, while in 2025 it took a cornerstone stake in CATL's HK listing; these are shown separately below.

Holdings & weights

Q1 2026 · 13F (as of Mar 31, 2026)

Weights are by market value, from real 13F / daily disclosure. This is a snapshot and will change — see live: Hillhouse HHLR Advisors 13F · 13f.info

PinduoduoPDDTrimmed −61%
25.44%

His long-standing #1 Chinese position — cut hard this quarter but still the top holding.

Analyze through a master's lens
AlibabaBABATrimmed −55%
18.4%

A flagship China-bull holding, also sharply trimmed this quarter.

Analyze through a master's lens
BeOne MedicinesONC
18.36%

The innovative-drug leader (formerly BeiGene) at the heart of his biotech thesis — held steady.

Analyze through a master's lens
Futu HoldingsFUTUTrimmed −13%
11.6%

An online-brokerage position, trimmed modestly this quarter.

Analyze through a master's lens
Legend BiotechLEGN
6.47%

A CAR-T cell-therapy leader extending his innovative-drug theme.

Analyze through a master's lens
ArriVent BioPharmaAVBP
5.42%

An early-stage biotech holding.

Analyze through a master's lens
KE HoldingsBEKE
3.79%

A Chinese real-estate-platform position.

Analyze through a master's lens
Marvell TechnologyMRVLNew this Q
1.01%

A new AI-semiconductor position this quarter.

Analyze through a master's lens
CATL (H-share)03750.HKNot in U.S. 13F

Subscribed ~US$200M as a cornerstone investor in CATL's May 2025 HK listing — a rare recent China add. Not in the U.S. 13F.

Analyze through a master's lens
LONGi Green Energy601012.SSNot in U.S. 13F

A former A-share solar heavyweight, cut sharply in 2025 and out of the top-10 holders by Q1 2026. Not in the U.S. 13F.

Analyze through a master's lens

In their own words

Be a friend of time.

Flowing water doesn't race to be first; it competes to never stop.

Where to follow them

Primary sources. Read the original — don't settle for second-hand summaries.

Keep exploring

More people with a similar playbook

Zhang Lei Portfolio — Latest 13F Holdings & Buys/Sells | AI Hedge Fund